The 2025 European Hematology Association (EHA) Annual Meeting was grandly held both online and in-person, gathering top experts and scholars from the global hematology community. During the highly anticipated Presidential Symposium, Professor Nicola Cooper, an immune-hematologist from Imperial College London, delivered a keynote speech on "Immune Thrombocytopenia (ITP): From Biology to Targeted Therapy." She systematically reviewed the century-long evolution of ITP from its initial recognition to modern treatment, and by focusing on cutting-edge research, she outlined a clear roadmap for the future of personalized, precision therapy.

Editor's Note: Recently, the European Hematology Association (EHA) released its highly anticipated "Management of Aggressive Large B-cell Lymphoma (LBCL) Guidelines," providing comprehensive and authoritative clinical guidance for this highly heterogeneous…

In the high summer of 2025, the highly anticipated European Hematology Association (EHA) Annual Meeting was convened, bringing together top global experts in hematologic oncology to discuss cutting-edge progress and future directions in the field. In the Chronic Lymphocytic Leukemia (CLL) session, Dr. Daisy Diaz, a postdoctoral fellow from MD Anderson Cancer Center in the United States, representing the team of her mentor, Professor Deepa Sampath, delivered an exceptional presentation titled "A Study on Transcriptional Reprogramming and Survival Co-dependencies Following Venetoclax Resistance in Chronic Lymphocytic Leukemia." This research systematically unveiled the complex resistance mechanisms in CLL after the failure of Venetoclax treatment and proposed an innovative solution based on Proteolysis-Targeting Chimera (PROTAC) technology, offering a highly promising new approach for clinically overcoming dual-drug resistance.

Editor's Note: At the 30th Annual Congress of the European Hematology Association (EHA) held in Milan, Italy, global hematology experts gathered to share cutting-edge research and clinical breakthroughs. The prestigious…

Acute myeloid leukemia, subtype M2b (AML-M2b), was first identified in 1959 by Professor Chongli Yang at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences (CAMS), based on clinical features, bone marrow morphology, and cytology. He termed it “subacute granulocytic leukemia.” In 1973, Rowley and colleagues abroad reported the same leukemia subtype through cytogenetic methods. By the late 1990s, the team led by Professor Jianxiang Wang demonstrated that the chromosomal translocation t(8;21) leads to rearrangement of the AML1 and ETO genes, producing the AML1-ETO (RUNX1::RUNX1T1) fusion gene—the molecular hallmark of AML-M2b. This marker has since been widely applied in differential diagnosis and minimal residual disease (MRD) monitoring.

The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) will be held in Kumamoto, Japan, from September 24 to 27, 2025. One of the major…